170 related articles for article (PubMed ID: 31218844)
1. The immunostimulatory effects and pro-apoptotic activity of rhCNB against Lewis lung cancer is mediated by Toll-like receptor 4.
Yang J; Zhang H; Zhu Z; Gao Y; Xiang B; Wei Q
Cancer Med; 2019 Aug; 8(9):4441-4453. PubMed ID: 31218844
[TBL] [Abstract][Full Text] [Related]
2. Identification of a targeting-delivery peptide based on rhCNB.
Yang J; Gao Y; Zhu Z; Qin N; Wei Q
J Pept Sci; 2019 Jun; 25(6):e3159. PubMed ID: 30843319
[TBL] [Abstract][Full Text] [Related]
3. Genetically engineered drug rhCNB induces apoptosis and cell cycle arrest in both gastric cancer cells and hepatoma cells.
Guo Y; Huang Y; Tian S; Xie X; Xing G; Fu J
Drug Des Devel Ther; 2018; 12():2567-2575. PubMed ID: 30154649
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin subunit B is an immunostimulatory protein and acts as a vaccine adjuvant inducing protective cellular and humoral responses against pneumococcal infection.
Li J; Hu M; Guo J; Su Z; Wei Q
Immunol Lett; 2011 Oct; 140(1-2):52-8. PubMed ID: 21722668
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa mannose-sensitive hemagglutinin promotes T-cell response via toll-like receptor 4-mediated dendritic cells to slow tumor progression in mice.
Zhang M; Luo F; Zhang Y; Wang L; Lin W; Yang M; Hu D; Wu X; Chu Y
J Pharmacol Exp Ther; 2014 May; 349(2):279-87. PubMed ID: 24623801
[TBL] [Abstract][Full Text] [Related]
6. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 4 mediates the development of fatigue in the murine Lewis Lung Carcinoma model independently of activation of macrophages and microglia.
Vichaya EG; Ford BG; Quave CB; Rishi MR; Grossberg AJ; Dantzer R
Psychoneuroendocrinology; 2020 Dec; 122():104874. PubMed ID: 32979744
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and immunomodulatory effects of the intraperitoneal administration of Kanglaite in vivo in Lewis lung carcinoma.
Pan P; Wu Y; Guo ZY; Wang R; Wang YJ; Yuan YF
J Ethnopharmacol; 2012 Sep; 143(2):680-5. PubMed ID: 22867634
[TBL] [Abstract][Full Text] [Related]
9. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment.
Deguchi A; Tomita T; Ohto U; Takemura K; Kitao A; Akashi-Takamura S; Miyake K; Maru Y
Oncogene; 2016 Mar; 35(11):1445-56. PubMed ID: 26165843
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory effects exerted by Poria Cocos polysaccharides via TLR4/TRAF6/NF-κB signaling in vitro and in vivo.
Tian H; Liu Z; Pu Y; Bao Y
Biomed Pharmacother; 2019 Apr; 112():108709. PubMed ID: 30970514
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response.
Fang H; Wu Y; Huang X; Wang W; Ang B; Cao X; Wan T
J Biol Chem; 2011 Sep; 286(35):30393-30400. PubMed ID: 21730052
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4.
Yang J; Qin N; Zhang H; Yang R; Xiang B; Wei Q
Sci Rep; 2016 Apr; 6():24346. PubMed ID: 27090571
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway.
Chen T; Guo J; Han C; Yang M; Cao X
J Immunol; 2009 Feb; 182(3):1449-59. PubMed ID: 19155492
[TBL] [Abstract][Full Text] [Related]
14. Recombinant E. coli LLO/OVA induces murine BMDCs maturation via TLR4 and NOD1 receptor and promotes specific cytotoxic T cell immunity.
Xu M; Dai MS
Biomed Environ Sci; 2010 Oct; 23(5):350-6. PubMed ID: 21112482
[TBL] [Abstract][Full Text] [Related]
15. TLR2- and 4-independent immunomodulatory effect of high molecular weight components from Ascaris suum.
Favoretto BC; Silva SR; Jacysyn JF; Câmara NO; Faquim-Mauro EL
Mol Immunol; 2014 Mar; 58(1):17-26. PubMed ID: 24263181
[TBL] [Abstract][Full Text] [Related]
16. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432.
Okamoto M; Oshikawa T; Tano T; Ohe G; Furuichi S; Nishikawa H; Ahmed SU; Akashi S; Miyake K; Takeuchi O; Akira S; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
J Natl Cancer Inst; 2003 Feb; 95(4):316-26. PubMed ID: 12591988
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.
Merritt RE; Mahtabifard A; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1609-17. PubMed ID: 14666041
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 4 deficiency increases resistance in sepsis-induced immune dysfunction.
Cao C; Chai Y; Shou S; Wang J; Huang Y; Ma T
Int Immunopharmacol; 2018 Jan; 54():169-176. PubMed ID: 29149705
[TBL] [Abstract][Full Text] [Related]
20. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
